CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade

PURPOSE: Translational studies have shown that CDK12 mutations may delineate an immunoresponsive subgroup of prostate cancer, characterized by high neo-antigen burden. Given that these mutations may define a clinically distinct subgroup, we sought to describe outcomes to standard drugs and checkpoin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Schweizer, Michael T., Ha, Gavin, Gulati, Roman, Brown, Landon, McKay, Rana R., Dorff, Tanya, Hoge, Anna C.H., Reichel, Jonathan, Vats, Pankaj, Kilari, Deepak, Patel, Vaibhav, Oh, William K., Chinnaiyan, Arul, Pritchard, Colin C., Armstrong, Andrew J., Montgomery, R. Bruce, Alva, Ajjai
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7363399/
https://ncbi.nlm.nih.gov/pubmed/32671317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados